Supporting HER2+ mBC Patients in Later Lines: AE Management and the Role of the Multidisciplinary Team

Opinion
Video

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.

Video content above is prompted by the following:

  • What real world data following the use of Tucatinib and T-DXd that can help assist medical professionals.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Anatomical graphic of a person with a tumor in their left breast

First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

Russ Conroy
June 4th 2025
Article

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Graphic of a breast with a tumor.

Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

Bridget Hoyt
May 22nd 2025
Article

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

Line illustration of a breast on a yellow background

How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS
May 16th 2025
Article

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Illustration of two people in lab coats doing work at a desk and at a microscope with a breast icon behind

Avutometinib Triplet Active in Resistant HR+/HER2– Breast Cancer

Jax DiEugenio
May 7th 2025
Article

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.

Anatomic image of a breast

T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

Ashling Wahner
April 23rd 2025
Article
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article